Investors Sue Beta Bionics Over Securities Fraud Allegations
Investors who experienced losses in Beta Bionics stock are being invited to lead a securities fraud class action lawsuit against the company. The deadline to participate is November 3, 2026.
BENSALEM TOWNSHIP, Pa. – Investors who have suffered substantial losses in Beta Bionics, Inc. (BBNX) have an opportunity to lead a securities fraud class action lawsuit. The Law Offices of Howard G. Smith has announced that interested investors must contact the firm before the November 3, 2026 deadline to participate.
The lawsuit alleges that between July 30, 2025, and February 24, 2026, the company and its executives made materially false or misleading statements and failed to disclose adverse information about Beta Bionics' business, operations, and prospects. Specifically, the complaint claims the company omitted information regarding an FDA Form 483 and underlying safety issues.
According to the allegations, the FDA Form 483 identified over 18,000 complaints, including numerous life-threatening hypoglycemic events, which the company allegedly failed to investigate or report to the FDA. The suit further claims that Beta Bionics' assurances about advanced remediation efforts and downplaying FDA concerns were misleading, as the observed issues were more complex than represented.
The complaint also states that the company failed to implement required corrective actions (CAPA) without justification, and that its positive statements about business prospects lacked a reasonable basis. Investors who lost money are encouraged to contact the Law Offices of Howard G. Smith for more details or to discuss their legal rights.